Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

Objective: To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL). Methods: Patients received InO plus R-GDP (21-day cycle...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangha, Randeep, Davies, Andrew, Dang, Nam H., Ogura, Michinori, MacDonald, David A., Ananthakrishnan, Revathi, Paccagnella, M. Luisa, Vandendries, Erik, Boni, Joseph, Goh, Yeow Tee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614242/
https://www.ncbi.nlm.nih.gov/pubmed/28959500
http://dx.doi.org/10.1080/21556660.2017.1315336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614242/
https://www.ncbi.nlm.nih.gov/pubmed/28959500
http://dx.doi.org/10.1080/21556660.2017.1315336

Ejemplares similares